PR-Section 8 and 9

Under the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it displays a valid OMB control number. PTO Form 1963 (Rev 05/2006)

OMB No. 0651-0055 (Exp 07/31/2018)

---

Under the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it displays a valid OMB control number. PTO Form 1963 (Rev 05/2006)

OMB No. 0651-0055 (Exp 07/31/2018)

Combined Declaration of Use and/or Excusable Nonuse/Application for Renewal of Registration of a Mark under Sections 8 & 9

To the Commissioner for Trademarks:

REGISTRATION NUMBER: 1452879
REGISTRATION DATE: 08/18/1987

MARK: THERAFLU

The owner, NOVARTIS CONSUMER HEALTH S.A., private company limited by shares (prc) legally organized under the laws of Switzerland, having an address of
      ROUTE DE I'ETRAZ
      1197 PRANGINS,
      Switzerland
      XXXX (authorized)
is filing a Combined Declaration of Use and/or Excusable Nonuse/Application for Renewal of Registration of a Mark under Sections 8 & 9.

For International Class 005, the mark is in use in commerce on or in connection with all goods/services, or to indicate membership in the collective membership organization, listed in the existing registration for this specific class: COUGH AND COLD PREPARATION ; or, the owner is making the listed excusable nonuse claim.

The owner is submitting one(or more) specimen(s) showing the mark as used in commerce on or in connection with any item in this class, consisting of a(n) digital image of the mark depicted on product packaging.
Specimen File1

MISCELLANEOUS STATEMENTS
Registrant hereby confirms that the chain of title of ownership for NOVARTIS CONSUMER HEALTH S.A. has not changed, but rather in compliance with the Office's requirements, we have further clarified the Entity type.

The registrant's current Attorney Information: Charles M. Atkinson of  GlaxoSmithKline
      LGTM - NY0300
      5 Crescent Drive
      Philadelphia, Pennsylvania 19112
      United States
The phone number is 484-431-5142.
The fax number is 215-751-7051.
The email address is trademarks@gsk.com. (authorized)
The docket/reference number is TMR 5120589/.

The registrant's proposed Attorney Information: Charles M. Atkinson of  GSK
      LGTM - NY0300
      5 Crescent Drive
      Philadelphia, Pennsylvania 19112
      United States The docket/reference number is 81239083/MAS.
The Other Appointed Attorney(s): Terence A. Dixon, Christopher M. Hanes and Angela L. Wilson.

The phone number is 484-431-5142.
The fax number is 215-751-7051.
The email address is trademarks@gsk.com. (authorized)
The registrant's current Correspondence Information: Charles M. Atkinson of  GlaxoSmithKline
      LGTM - NY0300
      5 Crescent Drive
      Philadelphia, Pennsylvania 19112
      United States
The phone number is 484-431-5142.
The fax number is 215-751-7051.
The email address is trademarks@gsk.com. (authorized)
The docket/reference number is TMR 5120589/.

The registrant's proposed Correspondence Information: Charles M. Atkinson of  GSK
      LGTM - NY0300
      5 Crescent Drive
      Philadelphia, Pennsylvania 19112
      United States The docket/reference number is 81239083/MAS.

The phone number is 484-431-5142.
The fax number is 215-751-7051.
The email address is trademarks@gsk.com. (authorized)

A fee payment in the amount of $425 will be submitted with the form, representing payment for 1 class(es), plus any additional grace period fee, if necessary.


Declaration

	Unless the owner has specifically claimed excusable nonuse, the mark is in use in commerce on or in connection with the goods/services or to indicate membership in the collective membership organization identified above, as evidenced by the attached specimen(s).
	The specimen(s) shows the mark as currently used in commerce on or in connection with the goods/services/collective membership organization.
	The registrant requests that the registration be renewed for the goods/services/collective organization identified above.
	To the best of the signatory's knowledge, information, and belief, formed after an inquiry reasonable under the circumstances, the allegations and other factual contentions made above have evidentiary support.
	The signatory being warned that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. § 1001, and that such willful false statements and the like may jeopardize the validity of this submission, declares that all statements made of his/her own knowledge are true and all statements made on information and belief are believed to be true.

Signature: /tad/    Date: 04/06/2017
Signatory's Name: Terence A. Dixon
Signatory's Position: Trademark Counsel (Member of the bars of Pennsylvania & New York)
Signatory's Phone: 2157517653

Mailing Address (current):
   GlaxoSmithKline
   5 Crescent Drive
   Philadelphia, Pennsylvania 19112

Mailing Address (proposed):
   GSK
   5 Crescent Drive
   Philadelphia, Pennsylvania 19112

Serial Number: 73637147
Internet Transmission Date: Thu Apr 06 11:44:49 EDT 2017
TEAS Stamp: USPTO/S08N09-XXX.XX.XX.X-201704061144490
94850-1452879-580f1d437ff38529f9361d484f
9ac270da385ca82ce7bc189b5cd6fd536fb5829-
DA-11757-20170406102249834881